FIELD: medicine.
SUBSTANCE: invention refers to medicine and concerns a method of inhibiting the total activity of the basic (alkaline) phospholipase A2 of mononuclear cells, involving administering to the animal a drug, wherein the agent used is composition containing 1-(hermatran-1-yl)-1-oxyethylamine and a pharmaceutically acceptable aqueous carrier to be administered intramuscularly in an animal in dose of 10 mg of the active substance/kg daily for 2 months.
EFFECT: invention provides inhibition of total activity of basic (alkaline) phospholipase A2 of mononuclear cells.
4 cl, 1 ex, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
USE OF 1-(HERMATRANE-1-YL)-1-OXYETHYLAMINE FOR INHIBITING TOTAL ACTIVITY OF BASIC (ALKALINE) PHOSPHOLIPASE A2 OF MONONUCLEAR CELLS | 2020 |
|
RU2732883C1 |
USE OF BIS(Μ-TARTRATO)DI(Μ-HYDROXO)GERMANATE (IV) TRIETHANOLAMMONIUM FOR INHIBITING TOTAL ACTIVITY OF BASIC (ALKALINE) PHOSPHOLIPASE A2 OF MONONUCLEAR CELLS | 2020 |
|
RU2733166C1 |
METHOD OF INHIBITING TOTAL ACTIVITY OF BASIC (ALKALINE) PHOSPHOLIPASE A2 OF MONONUCLEAR CELLS USING BIS(Μ-TARTRATO)DI(Μ-HYDROXO)GERMANATE (IV) TRIETHANOLAMMONIUM | 2020 |
|
RU2732880C1 |
APPLICATION OF PROTATRAN 4-CHLORO-2-METHYLPHENOXYACETATE FOR EXHAUSTING OF MONONUCLEAR CELLS BASIC (ALKALINE) PHOSPHOLIPASE a2 TOTAL ACTIVITY | 2016 |
|
RU2619860C1 |
USE OF 1-(GERMATRAN-1-YL)-1-HYDROXYETHYLAMINE FOR INHIBITING THE DEVELOPMENT OF ATHEROSCLEROSIS IN THE EXPERIMENT | 2020 |
|
RU2746321C1 |
METHOD OF ATHEROGENESIS CORRECTION IN EXPERIMENT USING 1-(GERMATRAN-1-YL)-1-OXYETHYLAMINE | 2020 |
|
RU2741906C1 |
USING COMPLEX OF TRIS-(2-HYDROXYETHYL)AMINE AND ZINC BIS-(2-METHYLPHENOXYACETATE) (CINKATRAN) AS AGENT SUPPRESSING TOTAL ACTIVITY OF BASIC (ALKALINE) MONONUCLEAR PHOSPHOLIPASE A2 | 2014 |
|
RU2546537C1 |
1-HYDROXYGERMATRANE USAGE FOR INHIBITING THE DEVELOPMENT OF ATHEROSCLEROSIS IN THE EXPERIMENT | 2020 |
|
RU2742972C1 |
METHOD FOR CORRECTING ATHEROGENESIS EXPERIMENTALLY USING 1-HYDROXYGERMATRANE | 2020 |
|
RU2741229C1 |
AGENT MODULATING ACID PHOSPHOLIPASE A1 ACTIVITY | 2010 |
|
RU2445087C1 |
Authors
Dates
2020-09-24—Published
2020-05-14—Filed